Male Infertility Market Size & Growth Forecast 2027–2036, By Segments (Treatment, Test), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape

Market Size and Growth Outlook

Male Infertility Market size was over USD 4.9 billion in 2026 and is likely to grow at a 4.66% CAGR between 2027 and 2036, reaching USD 7.73 billion by 2036. The industry revenue for 2027 is assessed at USD 5.09 billion.

• Base Year Value (2026): USD 4.9 billion
• CAGR (2027-2036): 4.66%
• Forecast Year Value (2036): USD 7.73 billion
• Historical Data Period: 2022-2026
• Largest Region: Europe
• Forecast Period: 2027-2036

Male Infertility Market Intelligence Snapshot:

• Regional Market Dynamics:

  • Europe accounted for 39.54% of the market in 2026, supported by established reproductive healthcare systems, specialist fertility clinics, structured referrals, and broad access to advanced diagnostics and treatments.
  • Asia Pacific is projected to grow at a 5.76% CAGR as fertility care access expands, specialist treatment infrastructure improves, and more patients enter diagnosis-led reproductive care pathways.

• Segment Momentum:

  • This segment held a 67.95% share in 2026 because it addresses a broad range of infertility causes and provides effective treatment pathways for clinically significant reproductive challenges.
  • Computer Assisted Semen Analysis is the fastest-growing segment as it improves testing consistency, reduces manual variability, and supports more standardized diagnostic workflows in fertility clinics.

• Market Expansion Drivers:

  • Rising global infertility rates driving increased adoption of assisted reproductive technologies.
  • Increasing use of DNA fragmentation testing improving male infertility diagnostics accuracy.
  • Lifestyle-related risk factors such as obesity and smoking increasing male reproductive health issues.

• Leading Market Participants:

  Major companies in the male infertility market include Bayer AG (Germany), Aytu BioPharma, Inc. (United States), Cadila Pharmaceuticals Limited (India), Halotech DNA, S.L. (Spain), Merck KGaA (Germany), Intas Pharmaceuticals Ltd. (India), CooperSurgical, Inc. (United States), Vitrolife AB (Sweden), Ferring Pharmaceuticals (Switzerland), SCSA Diagnostics, Inc. (United States).

Unlock Complete Insights

Global Market Forecast Snapshot:

• Market Outlook:

  • 2026 Market Size: USD 4.9 billion
  • 2027 Estimated Market Size: USD 5.09 billion.
  • Projected Market Size: USD 7.73 billion by 2036
  • Growth Forecasts: 4.66% CAGR (2027-2036)

• Regional and Segment Outlook:

  • Leading Regional Market: Europe
  • High-Growth Regional Hub: Asia Pacific
  • Core Revenue Segment: Assisted Reproductive Technology and Varicocele Surgery (Treatment) | DNA Fragmentation Technique (Test)
  • Emerging Opportunity Segment: Assisted Reproductive Technology and Varicocele Surgery (Treatment) | Computer Assisted Semen Analysis (Test)

Market Growth Drivers and Industry Trends

Rising global infertility rates driving increased adoption of assisted reproductive technologies

Increasing recognition of infertility as a reproductive health concern is encouraging more couples to seek specialized evaluation and treatment, supporting the male infertility market through greater utilization of assisted reproductive technologies. Male reproductive factors contribute substantially to difficulties in conception, prompting diagnostic assessment before selecting appropriate interventions such as intrauterine insemination, in vitro fertilization, or intracytoplasmic sperm injection. Improvements in fertility care pathways and greater willingness to pursue specialized reproductive services are also encouraging earlier evaluation of sperm quality and reproductive function.

Increasing use of DNA fragmentation testing improving male infertility diagnostics accuracy

Greater attention to sperm quality beyond conventional semen parameters is strengthening demand for advanced diagnostic approaches, which will boost male infertility market development through increased use of DNA fragmentation testing. Sperm DNA integrity can provide additional information about reproductive potential when standard measures such as concentration, motility, and morphology do not fully explain infertility. Incorporating DNA fragmentation assessment into selected fertility evaluations can help clinicians identify underlying sperm-related factors and refine treatment decisions, particularly for patients experiencing unexplained infertility or repeated assisted reproduction difficulties.

Lifestyle-related risk factors such as obesity and smoking increasing male reproductive health issues

Lifestyle factors are increasingly recognized as contributors to impaired reproductive function, creating a broader need for male fertility assessment and treatment. Obesity, smoking, sedentary behavior, poor dietary patterns, and related metabolic stresses can adversely affect hormonal balance, sperm production, motility, and overall sperm quality, thereby supporting male infertility market demand. Growing awareness of these risk factors is encouraging men to seek reproductive health evaluations and prompting fertility specialists to assess lifestyle and metabolic conditions alongside conventional semen analysis when determining potential causes of impaired fertility.

Growth Driver Assessment Framework
Growth Driver	Impact On CAGR	Regulatory Influence	Geographic Relevance	Adoption Rate	Impact Timeline
Rising prevalence of male infertility	1.80%	Short term (≤ 2 yrs)	North America, Europe (spillover: Asia Pacific)	High	Fast
Adoption of advanced diagnostics and treatments	1.70%	Medium term (2–5 yrs)	Europe, Asia Pacific (spillover: North America)	Medium	Moderate
Expansion of fertility clinics and telemedicine solutions	1.60%	Long term (5+ yrs)	North America, Europe (spillover: Asia Pacific)	Medium	Slow
Rising global infertility rates driving increased adoption of assisted reproductive technologies	2.90%	High	Europe, Asia Pacific	High	Near Term
Increasing use of DNA fragmentation testing improving male infertility diagnostics accuracy	2.40%	Moderate	North America, Europe	Medium	Mid Term
Lifestyle-related risk factors such as obesity and smoking increasing male reproductive health issues	2.60%	Moderate	North America, Asia Pacific	High	Near Term

Regional Demand Dynamics

Europe (Largest Region) vs Asia Pacific (Fastest-Growing Region)

Europe dominated the male infertility market in 2026, holding a 39.54% share, supported by developed reproductive healthcare infrastructure, greater awareness of male reproductive health, and broad access to specialized diagnostic and treatment services. Increasing recognition of male factors in infertility is encouraging couples to pursue comprehensive fertility assessments and specialized interventions. The region's established healthcare systems facilitate access to diagnostic testing, assisted reproductive procedures, and fertility counseling, while improvements in laboratory techniques are supporting more precise evaluation of reproductive conditions. Greater openness toward fertility treatment and continued emphasis on reproductive health services are also reinforcing demand across the region.

Asia Pacific represents the fastest-growing region for the male infertility market, supported by rising awareness of reproductive health, improving healthcare access, and expanding availability of fertility services. Urbanization and changing lifestyles are contributing to greater attention toward infertility diagnosis, while increased health awareness is encouraging men to seek specialized medical evaluation. Investments in fertility clinics, diagnostic laboratories, and advanced reproductive technologies are improving treatment accessibility across the region. Growing acceptance of assisted reproductive care, combined with expanding healthcare infrastructure and increasing demand for specialized fertility services, is creating substantial opportunities for market development.

Key Country Insights

United States

Comprehensive Fertility Care

The U.S. male infertility market benefits from broader access to reproductive diagnostics, fertility clinics, and assisted reproductive technologies. Healthcare providers increasingly promote earlier evaluation and personalized treatment pathways for male reproductive health.

Japan

Early Assessment Focus

Japan is encouraging earlier assessment of male infertility as awareness of reproductive health continues to improve. Fertility clinics increasingly integrate advanced diagnostics with personalized treatment plans to address diverse underlying causes.

South Korea

Specialized Fertility Services

South Korea continues expanding specialized fertility services that include comprehensive male infertility evaluation and treatment. Healthcare providers increasingly combine advanced diagnostics with assisted reproductive technologies to support individualized patient care.

Germany

Diagnostic Pathway Enhancement

Germany prioritizes evidence-based diagnosis and multidisciplinary management within the male infertility market. Fertility specialists increasingly adopt advanced laboratory testing and individualized treatment strategies to improve clinical decision-making.

France

Integrated Reproductive Care

France supports the male infertility market through coordinated reproductive healthcare and wider access to fertility assessments. Clinical practice increasingly emphasizes identifying male factors early to improve overall treatment planning for couples.

Italy

Personalized Treatment Approach

Italy is strengthening male infertility services through improved diagnostic capabilities and specialized fertility centers. Healthcare professionals increasingly tailor treatment plans according to individual clinical profiles and reproductive goals.

Segment Leadership and Growth Trends

 

Treatment Segment Analysis: Assisted Reproductive Technology and Varicocele Surgery (Largest & Fastest-Growing Segment)

The male infertility market was led by the assisted reproductive technology and varicocele surgery segment, which accounted for 67.95% share in 2026. Its strong position reflects the clinical importance of these interventions in addressing underlying reproductive challenges and improving the likelihood of conception. Assisted reproductive techniques provide treatment pathways for patients with varying degrees of male-factor infertility, while varicocele surgery can address a correctable anatomical condition associated with impaired sperm production and quality. Increasing awareness of male reproductive health, greater willingness to seek specialized fertility care, and continued improvements in diagnostic and treatment approaches are supporting the segment's broad clinical adoption. Its combined role in addressing both direct causes and fertility outcomes also contributes to its continued prominence.

Test Segment Analysis: DNA Fragmentation Technique (Largest Segment) vs Computer Assisted Semen Analysis (Fastest-Growing Segment)

The DNA fragmentation technique segment held the largest share of the male infertility market at 23.51% in 2026, supported by growing recognition of sperm DNA integrity as an important factor in evaluating male reproductive potential. Conventional semen parameters do not always capture underlying sperm quality issues, making DNA fragmentation assessment valuable for patients experiencing unexplained infertility, recurrent reproductive failure, or poor treatment outcomes. Greater emphasis on comprehensive fertility evaluation is encouraging clinicians to incorporate advanced testing methods that provide deeper insight into sperm function and reproductive prospects.

Computer assisted semen analysis is gaining momentum as fertility centers increasingly adopt automated and objective approaches to evaluate semen characteristics. These systems can support standardized assessment of sperm concentration, motility, morphology, and other parameters while reducing dependence on subjective manual interpretation. The broader shift toward digital diagnostics, improved laboratory reproducibility, and data-supported fertility management is creating favorable conditions for wider adoption. As fertility providers seek efficient tools that can enhance diagnostic consistency and treatment planning, computer assisted semen analysis is becoming increasingly relevant within male infertility testing.

Report Segmentation
Segment	Sub-Segment	Largest Segment	Fastest Growing Segment
Treatment	Assisted Reproductive Technology and Varicocele Surgery, Medication	Assisted Reproductive Technology and Varicocele Surgery	Assisted Reproductive Technology and Varicocele Surgery
Test	DNA Fragmentation Technique, Oxidative Stress Analysis, Microscopic Examination, Sperm Agglutination, Computer Assisted Semen Analysis, Sperm Penetration Assay, Others	DNA Fragmentation Technique	Computer Assisted Semen Analysis

Competitive Landscape and Market Positioning

Top players in the male infertility market:

1. Bayer AG (Germany)

2. Aytu BioPharma Inc. (United States)

3. Cadila Pharmaceuticals Limited (India)

4. Halotech DNA S.L. (Spain)

5. Merck KGaA (Germany)

6. Intas Pharmaceuticals Ltd. (India)

7. CooperSurgical Inc. (United States)

8. Vitrolife AB (Sweden)

9. Ferring Pharmaceuticals (Switzerland)

10. SCSA Diagnostics Inc. (United States)

The male infertility market is witnessing increased attention due to rising awareness and diagnostic advancements. Improved therapeutic approaches are enabling more targeted treatment pathways. The male infertility market is also shaped by innovation in reproductive technologies and personalized care models. Continuous development is expanding access to effective fertility solutions.

Industry Development/News

Company Name	Date	Key Development
Ontario Government	May-26	The provincial government’s $100 million investment to expand publicly funded fertility services significantly bolsters reproductive healthcare infrastructure. This initiative improves patient access to diagnostic pathways and treatments, indirectly supporting a broader patient base and increasing clinical demand for male-factor infertility services across the healthcare system.
Nova IVF Fertility	Jul-25	The opening of the company's 100th fertility center marks a major expansion of its clinical footprint across 63 Indian cities. By increasing accessibility in tier 2 and tier 3 regions, this expansion enhances the distribution network for assisted reproductive services and addresses growing demand for specialized fertility diagnostics and treatment.
Farwaniya Hospital	Aug-24	The inauguration of a new Fertility and Assisted Reproduction Unit in Kuwait significantly enhances national reproductive healthcare capacity. By providing comprehensive diagnostic testing and advanced treatment options, the facility strengthens the local healthcare infrastructure and improves access to specialized reproductive technologies for patients within the region.
Archish Fertility & IVF	Jul-24	The launch of a new facility in HSR Layout, India, expands the provider’s clinical network and regional reach. The unit integrates specialized male infertility diagnostics and treatment into its service offerings, strengthening local market access to comprehensive reproductive healthcare and supporting the firm's overall competitive positioning in fertility services.
Ferring Pharmaceuticals	Jun-24	The launch of a digital assessment tool and educational platform represents a strategic move to optimize the patient funnel toward early diagnosis. By addressing awareness gaps, the platform facilitates better patient engagement and clinical navigation, ultimately supporting the commercialization of diagnostic and treatment pathways within the male infertility segment.
FertGroup; Future Fertility	Apr-24	The strategic partnership to deploy AI-enabled oocyte assessment software across Brazilian clinics represents a material advancement in digital reproductive analytics. This technology integration improves clinical decision-making and standardizes embryo evaluation processes, enhancing the quality of care and operational efficiency within the provider’s network to drive better treatment outcomes.
AINU Chennai	Feb-24	The inauguration of a dedicated andrology department provides a consolidated hub for male-specific reproductive healthcare. By integrating specialized diagnostics, sexual dysfunction management, and advanced infertility treatments, the institution strengthens its clinical infrastructure and enhances its capacity to manage complex male-factor infertility cases with a specialized, multidisciplinary approach.